Visual Field Loss in a Case of Recurrent Cystic Craniopharyngioma During Concomitant Treatment With Pegylated Interferon α-2b.

Abstract

A 13-year-old male with suprasellar cystic craniopharyngioma initially controlled with sequential subtotal resections and proton-beam irradiation was later treated with intracystic pegylated interferon α-2b due to progression and a lack of further surgical options. After initial successful control of recurrent cyst enlargement and stabilization of the ophthalmic examination, progressive and irreversible visual field loss ensued. Imaging revealed intracranial leakage from the intracystic catheter, and direct administration of interferon α-2b was discontinued. Given the recent interest in interferon α-2b, oncologists are advised to vigilantly monitor patients for signs of local toxicity that may result from unintended leakage during intracystic delivery.

• Authors: Laura M Tiedemann, Peter Manley, Edward R Smith, Linda R Dagi
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 38 Issue 1 Pg. e26-8 (Jan 2016) ISSN: 1536-3678 [Electronic] United States
• PMID: 26558808 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• peginterferon alfa-2b

Topics

• Adolescent
• Antineoplastic Agents (administration & dosage, adverse effects)
• Craniopharyngioma (drug therapy)
• Cysts (pathology)
• Drug Administration Routes
• Humans
• Interferon alpha-2
• Interferon-alpha (administration & dosage, adverse effects)
• Male
• Neoplasm Recurrence, Local (drug therapy)
• Pituitary Neoplasms (drug therapy)
• Polyethylene Glycols (administration & dosage, adverse effects)
• Recombinant Proteins (administration & dosage, adverse effects)
• Vision Disorders (chemically induced)
• Visual Fields (drug effects)